Table 1.
Baseline Characteristics
| INDOOR Trial | ||||
|---|---|---|---|---|
| Characteristic | All (N = 42) | Switch Arm (n = 20) | Control Arm (n = 22) | P Value |
| Age, y, median (IQR) | 49 (46–54) | 49 (45–53) | 53 (46–55) | .21 |
| Sex | ||||
| Female | 12 (29) | 8 (40) | 4 (18) | .17 |
| Male | 30 (71) | 12 (60) | 18 (82) | |
| HIV infection route | ||||
| IDU | 23 (55) | 10 (50) | 13 (58) | .02 |
| MSM | 3 (7) | 0 | 3 (14) | |
| Heterosexual | 13 (31) | 10 (50) | 3 (14) | |
| Unknown | 3 (7) | 0 | 3 (14) | |
| Time since diagnosis of HIV, y, median (IQR) | 17.5 (11.8–25) | 16 (11–23.8) | 20 (13.8–25.3) | .19 |
| Time since initiation of cART, y, median (IQR) | 12 (6–18.3) | 12 (5.3–18) | 12 (7.5–19) | .65 |
| Time on current PI-based cART regimen, y, median (IQR) | 4 (3–7) | 4.5 (3–7) | 4 (2.8–8.5) | .96 |
| Time with suppressed VL, median (IQR) | 4 (3–8.3) | 3 (2.3–7.3) | 5.5 (3–9) | .23 |
| Nadir CD4+ count, cells/μL, median (IQR) | 199 (83–297) | 204 (95–259) | 197 (89–289) | .85 |
| Absolute CD4+ count, cells/μL, median (IQR) | 620 (495–920) | 610 (470–760) | 625 (503–1235) | .11 |
| % CD4+ T cells, median (IQR) | 33.2 (28.4–39.2) | 31.8 (28.3–35.2) | 35.6 (29.5–42.1) | .16 |
| Absolute CD8+ count, cells/μL, median (IQR) | 810 (605–1050) | 670 (605–890) | 905 (680–1215) | .19 |
| % CD8+ T cells, median (IQR) | 40.9 (34.8–47.8) | 40.4 (32.2–47.9) | 41.7 (35.8–47.7) | .51 |
| CD4:CD8 ratio, median (IQR) | 0.8 (0.6–1.1) | 0.8 (0.6–1.0) | 0.9 (0.7–1.1) | .68 |
| HIV-1 RNA copies/mL plasma, median (IQR) | <50 | <50 | <50 | .50 |
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: cART, combination antiretroviral therapy; HIV, human immunodeficiency virus; IDU, injection drug use; IQR, interquartile range; INDOOR, impact of Integrase-inhibitor DOlutegravir On the viral Reservoir; MSM, men who have sex with men; PI, protease inhibitor; VL, viral load.